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A short artificial antimicrobial 
peptide shows potential to prevent 
or treat bone infections
N. Bormann1,2, A. Koliszak1,3, S. Kasper1, L. Schoen1, K. Hilpert4, R. Volkmer5,8, J. Kikhney6,7 & 
B. Wildemann  1,2,3
Infection of bone is a severe complication due to the variety of bacteria causing it, their resistance 
against classical antibiotics, the formation of a biofilm and the difficulty to eradicate it. Antimicrobial 
peptides (AMPs) are naturally occurring peptides and promising candidates for treatment of joint 
infections. This study aimed to analyze the effect of short artificial peptides derived from an optimized 
library regarding (1) antimicrobial effect on different bacterial species, (2) efficacy on biofilms, and (3) 
effect on osteoblast‑like cells. Culturing the AMP‑modifications with Escherichia coli, Enterococcus 
faecalis, Pseudomonas aeruginosa, Staphylococcus aureus (including clinical isolates of MRSA and 
MSSA) and Staphylococcus epidermidis identified one candidate that was most effective against all 
bacteria. This AMP was also able to reduce biofilm as demonstrated by FISH and microcalorimetry. 
Osteoblast viability and differentiation were not negatively affected by the AMP. A cation concentration 
comparable to that physiologically occurring in blood had almost no negative effect on AMP activity 
and even with 10% serum bacterial growth was inhibited. Bacteria internalized into osteoblasts were 
reduced by the AMP. Taken together the results demonstrate a high antimicrobial activity of the AMP 
even against bacteria incorporated in a biofilm or internalized into cells without harming human 
osteoblasts.
Infections of bone are a severe complication and can result in a long-term treatment. Infected/contaminated 
material (tissue and implant) must be removed and the infection cleared. Staphylococcus aureus is the predom-
inant bacteria identified in fracture-fixation device associated infections (30%) followed by coagulase-negative 
staphylococci (22%), but also Gram-negative bacteria, enterococci, streptococci and other species may be iso-
lated1. The interaction of S. aureus with bone or especially osteoblasts is well investigated2. For example, S. aureus 
expresses several molecules (collagen adhesin, bone sialoprotein binding protein, MHC II analog protein) that 
support the binding with proteins of the extracellular matrix of bone, but also induces the secretion of inflamma-
tory factors and chemokines, and can induce apoptosis. A mechanism that allows S. aureus to persist protected 
from the immune system and most antibiotics is the internalization into host cells, especially osteoblast3. Within 
the last decades the number of resistant bacteria increased, resulting in more challenges for the treatment. Facing 
the impact of resistant bacteria on the human health and the health care systems, antimicrobial resistance (AMR) 
is identified as one of the major health problems4 resulting in the endorsement of a global action plan by the 
World Health Organization to tackle antimicrobial resistance. Besides the need to increase the awareness to this 
problem and the improvement of the antibiotic use, new antimicrobial active drugs must be developed. An inter-
esting group of antimicrobial active drugs are antimicrobial peptides (AMP). AMPs are widely found in nature 
and more than 2700 different AMPs are described so far [http://aps.unmc.edu/AP/main.php]5. As part of the 
innate immune system, the main task of AMPs is to build up the first defense barrier against entering pathogens. 
They are approximately between 10–50 amino acids in length and mostly cationic amphipathic peptides, which 
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can interact with the bacterial cell membrane. In recent years it became clear that they have different modes of 
actions, besides the “classical” one to cause cell lysis of bacteria6. AMPs act against Gram-positive and -negative 
bacteria, viruses and fungi, they do not easily induce resistance and can successfully attack bacteria within a bio-
film7–11. Due to their interaction with the cell membrane, which is beneficial for their antimicrobial activity, they 
might also interfere with eukaryotic cell membranes resulting in unwanted side effects in therapeutic application. 
It was previously reported that the activity of AMPs is reduced due to albumin present in human serum12, 13 and 
divalent cations such as Ca²+ and Mg²+ 12, 14. It is therefore recommended to use a cation-reduced medium for 
microbiological test15. However, this will not represent the physiological condition in the human body. In this 
study, the properties of five synthetic peptides were investigated. The used peptides were created by peptide array 
technology as previously described16–18. The effect of five 9mer peptides regarding the killing of various bacteria 
was investigated and the most effective peptide was used for further studies. With this peptide the effect on bac-
teria in a biofilm, the possible cytotoxic effect on human osteoblast-like cells, and the killing of bacteria within 
osteoblast-like cells was analyzed.
Results
Antimicrobial activity. The antimicrobial activity of five different AMPs was tested and gentamicin served 
as control. The inhibitory and bactericidal concentration was tested on seven Gram-positive or -negative bacterial 
strains (Fig. 1), two of them were clinical isolates. All tested AMPs inhibited bacterial growth at a concentration 
≤251 µg/ml. Except for E. faecalis, all bacteria were killed with the tested concentrations. Testing the influence of 
cations on the activity of the peptides revealed no major differences between the tested media. In some cases, e.g. 
P. aeruginosa, the MIC of AMPs was 3–8 concentrations higher for the medium with cations (MH++) compared 
to the medium without cations (MH−). Using clinical isolates of MRSA and MSSA, the AMP2 inhibited growth 
and was bactericidal, whereas gentamicin showed no growth inhibition of the MRSA as expected.
In a further experiment the possible effect of serum on AMP activity was investigated. AMP2 (67 µg/ml) was 
preincubated for 2 hours at 37 °C with different concentrations of FCS and then added to S. aureus. A dosage 
dependent inhibition of the AMP activity was detected (R2 = 0.863 with p = 0.000012), but even with 10% FCS 
the bacterial growth was less than 2% compared to the group without AMP (Table 1).
Effect on osteoblast like cells. All five AMPs were investigated regarding their possible cytotoxic effect 
on primary human osteoblast-like cells. As initial outcome parameter, cell viability was determined after incu-
bation with different concentrations of the AMPs or gentamicin. The lower concentrations (AMP1 < 100 µg/
Figure 1. Minimal inhibitory concentration (MIC) and minimal bactericidal concentration (MBC) in µg/ml 
for gentamicin (Genta) and for five different AMPs. MH++: Mueller-Hinton bouillon with cations (n = 4–8), 
MH−: Mueller-Hinton bouillon without cations (n = 4). Color code: green low concentration, dark orange high 
concentration needed for antimicrobial effect.
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ml, AMP2 < 267 µg/ml, AMP3 < 68 µg/ml, AMP4 < 251 µg/ml, AMP5 < 63 µg/ml) of the AMPs had no negative 
effect on cell viability, whereas the higher concentrations reduced cell viability significantly (p < 0.005) (Fig. 2A).
Alkaline phosphatase (AP) activity was determined after three days. Again, the low concentration of the AMP 
had no negative effect (except of AMP1, which reduced significantly AP activity at all concentrations), while with 
increasing AMP or gentamicin concentrations, AP activity was decreased. For AMP2-4, only the last three con-
centrations (125–541 µg/ml) reduced significantly the AP activity (p < 0.005) (Fig. 2B).
Because AMP2 was antimicrobial active at concentrations that had no negative effect on the viability and AP- 
activity of the osteoblast-like cells, this peptide was used for further studies.
The differentiation of the osteoblast-like cells was not affected by the low and high AMP concentration 
(17 + 133 µg/ml). There was no difference in the alkaline phosphatase activity between the groups cultivated 
with differentiation medium (DM) with or without AMP (Fig 3A). Cells in the cultivation medium (CM) showed 
only 20% AP activity compared to the control (DM without AMP). The mineralization assessed with alizarin red 
resulted in a deep red staining for the three DM groups (with and without AMP) and a faint staining for the CM 
group, which could be also quantitatively measured (Fig. 3B).
In addition, no effect on the osteogenic differentiation was observed for AMP2, as assessed by the expression 
of the markers runt-related transcription factor 2 (RUNX2), alkaline phosphatase (AP) and collagen type I alpha 
1 (Col1).The genes RUNX2 and AP were upregulated in all groups cultivated with DM with/without AMP but 
not for the CM group. Col1 showed an upregulation on day 7 for the three DM groups and decreased then again 
to the level of day 0. For the CM, no Col1 regulation could be observed (Fig. 3C).
The possible effect of the AMP2 on migration was investigated in a scratch assay over 48 hours. After 24 hours, 
the positive control (Fig. 4B, 10% FCS – 24 h), the CM without and with 4–33 µg/ml AMP2 resulted in 50–66% 
free-area. AMP2 concentration of 67 µg/ml reduced the migration of cells (Fig. 4B, 67 AMP2 – 24 h) and with 
133 µg/ml no migration was observed (data not shown). After 48 hours, a significant (p < 0.0001) closing of the 
gap could be seen for the positive control 10% FCS (Fig. 4B, 10% FCS – 48 h). AMP2 concentrations up to 33 µg/
ml resulted in a cell-free area of 12–28%. With 67 µg/ml AMP2, the gap size was 71%, while it was still complete 
open using 133 µg/ml (Fig. 4A). With the high AMP2 concentration (67 and 133 µg/ml) cells started to change 
morphology, which might also be due to the low FCS content (0.1% FCS) (Fig. 4B, 67 µg/ml AMP2 – 48 h).
The impact of AMP2 and rifampicin on internalized S. aureus was tested using human primary osteoblast-like 
cells. After 4 hours, no bacterial killing was seen in the control group (without AMP) and the bacteria continued 
to grow over 24 hours in the osteoblast-like cells. AMP2 (67 µg/ml) and rifampicin (7.5 µg/ml) decreased signif-
icantly the bacterial number after 4 hours and 24 hours. Cells treated with both AMP2 concentrations showed a 
bacterial load comparable to the starting point (0 hours). Compared to the untreated group, a strong inhibition of 
the bacteria was detectable (Fig. 5).
w/o AMP (0% FCS) 0% FCS 0.1% FCS 1% FCS 10% FCS
cfu/ml ± StD 141,111 ± 86,111 7 ± 9 37 ± 13 553 ± 255 2,078 ± 540
Table 1. Effect of FCS on AMP2 (67 µg/ml) activity. Shown are the results of bacterial growth in cfu/
ml ± standard deviation (n = 3). Data are shown as means with standard deviation. Regression analysis: 
R2 = 0.862 with p = 0.000012.
Figure 2. Human primary osteoblast-like cells were cultured with different concentrations of AMP and 
gentamicin for three days. Viability (A) and alkaline phosphatase (AP) activity (B) were determined. Values 
for AP were normalized to 104 cells and compared to control (untreated cells, 100%). Results are means of 
n = 6, cells from two donors, triplicates.). Data are shown as means with standard deviation. Kruskal-Wallis, 
Mann-Whitney, Bonferroni-Holm post-hoc test. Significant inhibition compared to the control group, viability: 
AMP1 ≥ 100 µg/ml, AMP2 ≥ 267 µg/ml, AMP3 ≥ 68 µg/ml, AMP4 ≥ 251 µg/ml, AMP5 ≥ 63 µg/ml; Alkaline 
phosphatase activity: AMP1 all concentrations, AMP2–4 ≥ 125 µg/ml, AMP5 ≥ 63 µg/ml.
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Figure 3. The differentiation experiment of the osteoblast-like cells was done with cultivation medium (CM), 
differentiation medium (DM) and DM with low (17 µg/ml) and high (133 µg/ml) AMP2. After 21 days alkaline 
phosphatase (AP) activity assay and staining (A) and alizarin red staining and quantification (B) were done 
(n = 6, cells from two donors, triplicates). Results were normalized to 104 cells and expressed in percentage to 
control (DM) which was set 100%. Data are shown as median with 25 and 75 percentiles. Kruskal-Wallis, Mann-
Whitney, Bonferroni-Holm post-hoc test: *Significant difference compared to the DM group, p ≤ 0.05. (C) 
Gene expression at days 0, 7, 14 and 21. Results are calculated with the ΔΔCt method with efficiency correction 
and normalization to the control (day 0 of differentiation) and 18 S ribosomal RNA used as a reference gene 
(n = 2). Data are shown as means with standard deviation.
Figure 4. Scratch assay with human primary osteoblast-like cells and different AMP2 concentrations (0–
133 µg/ml). Measurement of the gap was directly done after performing the scratch and after 24 and 48 hours 
incubation (n = 3–9, cells from one donor). (A) The cell-free area after 48 hours is shown in percentage of the 
gap compared to time point 0 hours ( = 100%). Positive control: CM with 10% FCS. Data are shown as median 
with 25 and 75 percentiles. Kruskal-Wallis, Mann-Whitney, Bonferroni-Holm post-hoc test: *Significant 
difference compared to group treated with 0 µg/ml AMP, p ≤ 0.05. (B) Exemplary pictures of positive control 
and 67 µg/ml AMP2 after 24 and 48 hours. The dotted lines mark the scratch. Scale bar 500 µm.
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Activity against biofilm. Two methods were used to investigate the effect of the AMP on biofilm. Using 
FISH, the biofilm was visualized and with microcalorimetry, the activity of the bacteria in the biofilm was 
quantified.
Using FISH, S. epidermidis biofilms were microscopically evaluated over the whole lengths of the PU wavers 
(approximately 100 microscopic fields per waver) and showed upon AMP2 exposure an reduction in biofilm 
thickness and number of FISH-positive cells. In addition, the biofilm structure was altered (Fig. 6A). For a more 
objective assessment of the AMP2 effect the areas were quantified. The treatment with AMP2 resulted in an 
up to 76% reduction of the biofilm area (4 µg/ml) compared to the untreated group (Fig. 6B). The percentage 
FISH-positive (Cy3) area was reduced by 86% or 90% for the group treated with 4 or 8 µg/ml AMP2 (Fig. 6C).
In a further experiment the S. aureus growth was quantified over time by calorimetry. The MIC of AMP2 for 
planktonic S. aureus was 8 µg/ml for all three tested bouillons and 1 µg/ml for gentamicin (results were compara-
ble to the broth microdilution method shown in Fig. 1).
To analyze the effect on the biofilm, AMP2 concentrations of 133–533 µg/ml were used and 128 µg/ml dapto-
mycin served as control. Daptomycin completely inhibited the biofilm growth (data not shown), which could also 
be proven by plating the samples and glass beads on agar plates (Fig. 7B). After 48 hours, AMP2 concentration of 
133 µg/ml significantly inhibited the biofilm by 13 ± 4% compared to the growth control. AMP2 concentration 
267 µg/ml resulted in a 35 ± 29% inhibition and 533 µg/ml AMP2 in 97 ± 1%, which were both significant. The 
high standard deviation for the concentration 267 µg/ml is because one of the six samples completely killed the 
bacteria, whereas five of them only inhibited the biofilm by 18–38% (Fig. 7A).
The MBCB was determined by plating samples and glass beads on the agar plates. All samples with 533 µg/ml 
AMP2 totally killed the S. aureus biofilm, as shown by no growth (Fig. 7B).
Local drug delivery. Performing a Zone of Inhibition test revealed that the AMP2 incorporated into the 
polymer-coating remained bioactive and inhibited the growth of S. aureus in a dose dependent manner (Fig. 8). 
The activity, however, was much lower compared to gentamicin, as also seen in the MIC/MIB (Fig. 1).
Discussion
A severe complication in orthopedic surgery is the development of an implant associated infection, which is dif-
ficult to treat and in most cases the removal of the implant combined with a prolonged antimicrobial therapy is 
necessary19. The ideal antimicrobial drug in this case will be active against different bacterial strains, bacteria in a 
biofilm or internalized in the eukaryotic cells of the host without harming them. Cationic antimicrobial peptides 
seem to be a promising substance class due to their broad activity and function. The present study investigated 
five cationic AMPs regarding their antimicrobial activity and effect on primary osteoblast-like cells. In addition, 
the potency to kill bacteria in a biofilm, as a severe complication associated with materials/implants used in 
orthopedic surgery, was investigated. The tested AMP modifications showed antimicrobial effectivity against all 
tested bacteria, including 2 clinical isolates. The AMP2 was also growth inhibitory and bactericidal for a clini-
cal MRSA isolate, which is a very important finding high lightening the potency of AMPs. The efficacy varied 
between the used modifications and a higher concentration compared to gentamicin was necessary (except for 
the MRSA) to inhibit bacterial growth and kill Gram-positive and -negative bacteria, which was also shown for 
other AMPs20. Due to the nature of the cationic AMPs, ions in the broth might cause an inhibition of the AMP21. 
Therefore, the concentration of Ca2+ and Mg2+ was varied in the broth and the effect on the AMP activity was 
investigated. In 80% of the experiments no or minor variations in the minimal inhibitory and bactericidal con-
centrations were detected for the 5 tested AMPs and the different bacteria. In 20% of the experiments the MIC or 
the MBC was 3 to 4 fold increased in the MH++ bouillon compared to the MH− bouillon. The main decrease of 
Figure 5. S. aureus internalized in human primary osteoblast-like cells were treated with 33 or 67 µg/ml 
AMP2 and 7.5 µg/ml rifampicin (rifam) for 4 hours and 24 hours (n = 7, cells from one donor). Data are 
shown as median with 25 and 75 percentiles. Kruskal-Wallis, Mann-Whitney, Bonferroni-Holm post-hoc test: 
*Significant compared to control group (0 µg/ml AMP), p ≤ 0.05.
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antimicrobial activity of gentamicin or the AMPs was seen for P. aeruginosa cultured in MH++. This change in the 
MIC of gentamicin against P. aeruginosa due to the supplementation of the medium with cations was also seen 
in a previous study indicating the impact of cations on antimicrobial activity of substances22. A prerequisite for 
the characterization of an antimicrobial peptide is the activity of the AMP in the presence of cations, representing 
more physiological conditions21. This was demonstrated in particular for AMP2, which was active against all the 
tested strains including two clinical isolates in cation enriched conditions.
The used antimicrobial peptides are part of a larger optimized peptide library. The five peptides were selected 
based on their good broad range activity and difference in structure. They were only 9 amino acids long and 
only composed of inexpensive amino acids. That would allow a cost effective large scale production and there-
fore low extra economic burden for the health care system in case a peptide would be used routinely to prevent 
or cure infection of the bone. In a previous study 49 peptides of this library were used and the antimicrobial 
activity mainly against Mycobacterium tuberculosis was investigated23. Beside M. tuberculosis also other bacterial 
strains were analyzed and this and the present study showed that the optimized peptides inhibit and also kill 
Gram-positive and -negative bacteria. The antimicrobial activity of the used peptides, however, was unexpectedly 
much higher than in the present study. To confirm that not the peptide caused this difference, the MICs against 
the reported strains was tested again by using the same provider of Mueller-Hinton broth as described before. We 
could verify the previously reported MICs and therefore exclude that peptides were the source of this difference 
in MICs. Further studies showed that for all-L peptides indeed there can be a strong strain dependency, caused 
by the amount of proteases produced or changes in the envelopment of the bacteria. All-D peptides that are very 
Figure 6. Fluorescence in situ hybridization (FISH) of S. epidermidis biofilms grown on polyurethane (PU) 
waver treated with 0, 4 or 8 µg/ml AMP2. (A) On the left hand, the panel shows the nucleic acid stain DAPI 
(blue) overlaid with the Cy3-labeled Staphylococcus-specific FISH-probe STAPHY (orange) for each group. The 
middle and right panels show either the separate DAPI or FISH Cy3 images in black and white of the respective 
colored image. AMP2 treatment led to a dramatic reduction of total biofilm area and fraction of FISH positive 
bacteria. Note also the altered fragmented appearance of the AMP treated biofilms. Scale bar = 10 µm. Pictures 
of 10 random areas per group were taken and results of digital images analysis are shown. (B) Total biofilm area 
(stained with DAPI). (C) Area of the FISH-positive bacteria (STAPHY-probe labelled with Cy3). n = 10 pictures 
per group. Data are shown as median with 25 and 75 percentiles.
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stable against proteases did not show these effects (unpublished results). MH broth is also not a well-defined 
media and could cause the bacteria to produce more or less proteases. In addition, the pre-cultivation, and the 
used cultivation method might have an influence. For the AMP2 used in the detailed analysis of the present study, 
the MIC difference for E. coli, P. aeruginosa, S. epidermidis was approximately two fold. Whereas it was much 
higher for S. aureus or E. feacalis, respectively. In a recent publication from Mikut at al. more than 3000 9mer pep-
tides were investigated in order to find activity rules24. The data confirmed previous observation that simple phys-
icochemical parameters are not good predictors, but the right balance between R, K and hydrophobic amino acids 
(I, V, F, Y, and W)25. There is also no positional preference for any amino acid. The current set of five peptides, 
however, is too small to correlate activity and sequence, especially given the photolytic effects described before.
Another substance that might have an influence on the antimicrobial activity of AMPs is serum and/or com-
ponents of the serum. Svenson et al. demonstrated that the presence of albumin induced a 10-fold increase of the 
minimal inhibitory concentration of lactoferricin-derivates for Staphylococcus aureus13. It is assumed that this 
decrease in activity is due to the 1:1 binding of the peptide and albumin. In a further study the effect of serum on 
hexcameric AMPs was investigated26. Depending on the modification of the peptide the antimicrobial activity or 
the protease resistance was increased. Testing the antimicrobial activity after addition of serum, however, showed 
a negative effect on the activity independent of the modification. Therefore, not only the degradation in the serum 
might impact the activity, but also the increased ionic-concentration and also binding with serum components 
might be responsible. In the present study serum decreased dosage dependent the activity of the AMP and this 
shows the importance of testing more physiological conditions than rather optimized culture conditions. Serum 
Figure 7. S.aureus biofilm was grown on glass beads and incubated with 133–533 µg/ml AMP2 and heat flow 
of the bacteria was measured over 48 hours. (A) Total heat over time. red: growth control (GC), gray: negative 
control (NC) - beads without bacteria, green: 133 µg/ml AMP2, purple: 267 µg/ml AMP2, black: 533 µg/ml µg/
ml AMP2 (n = 6). Kruskal-Wallis, Mann-Whitney, Bonferroni-Holm post-hoc test: *Significant compared to 
growth control, p ≤ 0.05. (B) After calorimetry measurement, samples and glass beads were plated on one half 
of a CA plate, respectively. Shown are exemplarily plates with medium sample on the left and three glas beads 
(circles) of 133, 267, 533 µg/ml AMP2 and 128 µg/ml daptomycin on the right side.
Figure 8. Zone of inhibition (ZOI) test of the AMP2 or gentamicin incorporated at different concentrations 
into a poly(D,L-lactide) coating (n = 3). Gentamicin was used in 10% w/w PDLLA, AMP2 ranged from 10, 20 to 
30% w/w PDLLA. (A) ZOI after 1 day, (B) ZOI after 3 days, (C) Quantification of the ZOI, n = 3. Data are shown 
as means with standard deviation.
www.nature.com/scientificreports/
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concentration of 0.1 and 1% decreased slightly the activity, and allowed us to perform the cytotoxicity tests and 
the internalization studies with primary osteoblast.
The highest concentration of all tested AMPs inhibited significantly the viability of the osteoblast-like cells, 
whereas concentrations necessary for killing all the tested bacteria had no negative effect on primary human 
osteoblast-like cells (except for AMP5). The most antimicrobial active and less harmful peptide -AMP2- was 
then used for further studies. Concentrations killing the different bacteria had no negative effect on osteogenic 
differentiation of the osteoblast-like cells and their migratory activity. This is an important aspect, because a bony 
ingrowth of the implant is a prerequisite for the successful healing and the prevention of an infection and this will 
only happen, if the host cells win the “race for the surface”27. If the local cells would be impaired by the antimicro-
bial therapy, this osteointegration would not occur increasing the risk of infections.
During the surgical debridement the infected periprosthetic tissue should be removed and antibiotic treat-
ment should kill all persisting bacteria. However, bacteria such as S. aureus and S. epidermidis can invade host 
cells and may be protected from the host immune system and antimicrobial therapy resulting in an infection at a 
later time point3. To address this possible complication the effectivity of the AMP2 reading the killing of internal-
ized bacteria was investigated. The concentration necessary to kill the bacteria under standard conditions (67 µg/
ml) inhibited significantly the bacterial load in osteoblast-like cells after 4 hours and inhibited their growth over 
a time-period of 24 hours. Due to the fact that this concentration had no negative effect on the cell viability and 
differentiation, it can be concluded that the mechanism of crossing mammalian membranes is non-damaging. 
This was recently also reported for modifications of cell penetrating peptides and AMPs, highlighting the potency 
of these two groups for new treatment strategies of intracellular infection28. Substitution of lysine with arginine 
increased the uptake of penetratin into HeLa WT cells. The substitution of arginine by lysine, however, had the 
opposite effect, high lightening the importance of both amino acids in this process. The AMP modification tested 
in the present study contains three arginine and one lysine residues, which might be responsible for the effective 
cell penetration seen and killing of internalized bacteria without harming the host cells. A comparison with the 
three other modified AMPs was not done but might show differences due to the differing ratios of arginine and 
lysine. However, the cell penetrating mechanism of peptides is not fully understood and might occur by direct 
translocation, endocytotic uptake or the formation of inverted miscelles29.
A further severe problem of implant associated infections is the formation of a biofilm that protects the bac-
teria30, 31. Penetration of antimicrobial active substances is affected by the biofilm and the altered susceptibility 
of the bacteria in the biofilm to antibiotics requires much higher dosages of substances to kill the bacteria32–34. 
Two independent approaches were used to analyze the effect of the AMP2 on biofilm. In the first approach bac-
teria and biofilm were visualized with a fluorescent probe directed against the ribosomal RNA that is specific for 
staphylococci35. In the second approach the energy production of the bacteria in the biofilm was measured36. 
Both methods showed that the AMP2 disturbed the biofilm (FISH) and killed the bacteria in the biofilm (micro-
calorimetry). The microcalorimentry data clearly showed that for eradication of the biofilm a much higher con-
centration was needed as for killing planktonic bacteria. The differences in the concentrations showing an effect 
for FISH or calorimetry can be explained on the one hand by the sensitivity of the two strains: S. epidermidis for 
FISH and S. aureus for microcalorimety. On the other hand by the different outcome measure: FISH visualizes the 
biofilm and detects changes in composition and cell count, whereas the calorimetry quantifies the heat develop-
ment of cells as a measure for viability. Therefore, smaller amounts of the AMP disturb the biofilm without killing 
all the bacteria. For killing bacteria in a biofilm higher concentrations are needed. The two strains were chosen 
because they are the most relevant pathogens causing orthopedic device infections and biofilm formation. The 
seen differences might be caused by differences in the biofilm formation and structure between S. aureus and S. 
epidermidis. For example, it was shown that poly-N-acetylglucosamine surface polysaccharide (PNAG or PIA) 
and extracellular DNA (ecDNA) have different structural roles in S. aureus and S. epidermidis leading to different 
effects of degrading enzymes37. Similar effects to the present study were seen in a previous study using also both 
methods to analyze the effect of antibiotic-loaded microparticles on S. aureus and S. epidermidis biofilms32. Both 
methods showed that S. aureus (MRSA) biofilm was inhibited by a lower Daptomycin concentration than S. epi-
dermidis biofilm. This underlines the differences of antimicrobial susceptibility of the two Staphylococci and also 
the differences in the method.
Due to the increasing development of bacterial resistance to classical antibiotics, new therapeutic approaches 
and alternatives to antibiotics are needed. At the moment, 19 clinical trials (Phase 1–3) for new antimicrobials 
including antibodies, probiotics, bacteriophages and vaccines are running38. How many will reach the registration 
and when, can only be estimated. A promising class of antimicrobial active substances are antimicrobial peptides 
(AMPs). Two AMP-like structures are approved for human use (Polymixin, Daptomycin) to treat skin infections 
and as reserve antibiotics, but three further AMPs failed FDA approval39. At the moment, for two AMPs clinical 
phase 1 or 2 studies are running38. Within the last years the US and European agencies (FDA and EMA) realized 
the urgent need for new antimicrobials and changed their guidelines to encourage the development and approval 
of new substances40. Taking the results of the present study together, the investigated AMP modifications showed 
an antimicrobial activity against Gram-positive and -negative bacteria at concentrations that have no negative 
effect on viability, differentiation and migration of osteoblast-like cells. Higher concentrations killed internal-
ized bacteria and bacteria within a biofilm. A preliminary release study proved the possibility to incorporate the 
AMP into a polymer coating for local drug release from an implant. The local release from the implant coating 
has several advantages: release of the active drug at the site of need, controlled release over a certain time period, 
reduction in applied drug concentration, and reduction of systemic drug load. The great advantage of the used 
drug delivery system compared to other experimental systems is the CE certification. Since 2005 this coating is 
used on intramedullary tibia nails loaded with gentamicin for infection prophylaxis41. But several other coating 
techniques are investigated in preclinical studies42–45. To combine the antimicrobial treatment with defect regen-
eration or in prosthetic surgery, other applications are also possible such as perioperative mixing of the AMP 
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with bone grafting material, such as autologous or allogeneic bone, polymers, tricalciumphosohate, bioglass or 
cement46, 47.
Focusing on the prevention and treatment of implant associated infections in orthopedics, the results of the 
present study are promising because the main obstacles are addressed: killing of planktonic, biofilm and inter-
nalized bacteria without impairing the function of host cells, allowing an osteointegration of the implant. Based 
on these encouraging results further optimization can provide researchers in academia and industry with lead 
compounds to specially address implant associated infections.
Material and Methods
Test substances. Cationic Antimicrobial Peptides (AMP) from an optimized peptide library were prepared 
using a solid-phase peptide synthesis procedure (SPPS). Briefly, SPPS was performed on a 50 μM scale using a 
multiple peptide synthesizer (Intavis, MultiPep RS, Tuebingen, Germany) and a standard Fmoc/t-Bu protocol, 
comprising double coupling at every cycle. Raw peptides were purified via RP-HPLC (peptide purity used in 
biologic assays was higher than 95%) and concentration was determined with NanoDrop 1000 UV/VIS spectro-
photometer (Thermo Fisher Scientific, USA). Five peptides from the optimized peptide library were initially used 
(Table 2, Fig. 9).
All C-termini (R-COO-) of peptides were amidated by ammonia to carboxamide groups (R-CO-NH2) and 
as a result, the former negatively charged C-terminus is turned to neutral. This enhances the overall positive 
charge of the antimicrobial peptides, which is one of the critical points for antimicrobial activity. Depending 
on the experiment, different antibiotics were use as reference: Gentamicin sulphate powder (~60% pure gen-
tamicin, 477.6 Da; Fujian Fukang Pharmaceutical Co., Ltd., China); Eremfat (pure rifampicin, 822.9 Da; Riemser, 
Germany) and Cubicin (pure daptomycin, 1619.7 Da; Novartis Pharma GmbH, Switzerland).
Bacterial strains. The strains Escherichia coli (ATCC 25922), Enterococcus faecalis (ATCC 29212), 
Pseudomonas aeruginosa (ATCC 27853), Staphylococcus aureus (ATCC 29213) were used. In addition, follow-
ing clinical isolates were used: Staphylococcus epidermidis (PIA 8400, isolated from blood cultures48), and two 
Staphylococcus aureus (MRSA and MSSA, both isolated from osteosyntheses material, kindly provided by Andrej 
Trampuz, Charité).
Minimal Inhibitory Concentration and Minimal Bactericidal Concentration. To determine the 
minimal inhibitory concentration (MIC), classical broth microdilution method was performed after protocols 
from Wiegand et al.15. The influence of cations was analyzed by using cation adjusted Mueller-Hinton bouillon 
II with 20–25 mg/l Ca2+ and 10–12.5 mg/l Mg2+ (MH++; BBL, Germany) or Mueller-Hinton bouillon without 
cations (MH−; Merck, Germany) (n = 4–8).
The maximal concentration of the AMPs was between 200–271 µg/ml. The differences in the AMP concen-
tration are due to the purity of the peptides (absorption coefficient from 5.19 to 9.36). A bacterial inoculum of 
1–5 × 105 colony forming units (cfu)/ml was incubated at 37 °C in an aerobe atmosphere (E. faecalis with 5% CO2) 
for 18–24 hours and the MIC was defined as the concentration without visible growth.
To identify the minimal bactericidal concentration (MBC), 80 µl of two wells with the determined MIC and 
two concentrations above this were plated on Columbia-agar (CA) plates with 5% sheep blood and incubated 
overnight at 37 °C.
In addition, the influence of fetal calf serum (FCS, containing 17 g/l albumin; Biochrom, Germany) on AMP 
activity was determined by preincubating 67 µg/ml of the AMP2 with 0–10% FCS at 37 °C for 2 hours followed by 
incubation with S. aureus for 3 hours. The control group, without AMP, was FCS free (n = 3).
Cytotoxicity, differentiation and migration. Human primary osteoblast-like cells were isolated from 
human femoral head with permission of the local ethic committee. The patients gave their written informed con-
sent. The tissue harvest was carried out in accordance with the local guidelines of the Charité-Universitätsmedizin 
Berlin and the study was approved by the ethics committee of the Charité-Universitätsmedizin Berlin 
(EA4/035/14).
(1) For the cytotoxicity test, 1 × 104 cells were seeded in 48-well plates with cultivation medium (CM) DMEM/
Ham’s F-12 (D/H; Biochrom, Germany) + 10% fetal calf serum (FCS; Biochrom, Germany) + 1% penicillin/strep-
tomycin (P/S; Biochrom, Germany) + 0.05 mM L-ascorbic-2 phosphate (L-Asc) + 0.05 mM β-glycerolphosphate 
(β-Glyc) and incubated overnight at 37 °C, 5% CO2 and 95% relative humidity. After adding the AMPs (3–542 µg/
ml - depending on the AMP) or gentamicin (8–1024 µg/ml) in CM with 1% FCS, without Pen/Strep, cells were 
cultured for three days. Cell viability was determined with an AlamarBlue® assay before adding the AMPs and 
Name Sequence[1] MW[2] Charge[3] IP [pH] GRAVY[4] composition[5]
AMP1 YRLRVKWKW 1338.64 5 12.2 −1.322 π+α+α+π+π
AMP2 KRRWRIWLV 1316.64 5 14 −0.744 +++π+απαα
AMP3 RTKKWIVWI 1232.54 4 14 −0.178 +ο++πααπα
AMP4 RRRIKIRWY 1351.67 6 12.6 −0.678 +++α+α+ππ
AMP5 WRKFWKYLK 1358.67 5 11.7 −1.411 π++ππ+πα+
Table 2. Information on tested antimicrobial peptides. [1]N-term: free amine; C-term: carboxamide, 
[2]Molecular weight [g/mol], [3]Net charge at pH 7 [4]Grand average of hydrophathicity (calculated using online 
software http://web.expasy.org/protparam)[5]+ basic; ο polar;π aromatic; α aliphatic.
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after 3 days. Alkaline phosphatase activity was measured on day 3. Cells from two donors were used and the 
experiments were done in triplicate (n = 6).
(2) The effect of the most antimicrobial active and less toxic AMP (AMP2) on osteoblast differentiation was 
investigated. Confluent cells were cultured for 21 days in cultivation medium (CM), differentiation medium (DM: 
D/H + 10% FCS + 1% P/S + 0.5 mM L-Asc + 10 mM β-Glyc + 100 nM dexamethasone + 1.5 mM calcium chlo-
ride) and DM with a low (17 µg/ml) and a high (133 µg/ml) AMP2 concentration. Medium was changed every 
3–4 days and fresh AMP was added by each change. Cells from two donors were used and the experiments were 
done in triplicate (n = 6).
Cell viability. Alamar Blue® (Biozol, Germany) was done according to the manufacturer’s instruction.
Alkaline phosphatase (AP) activity. Cells were incubated with 0.13% w/v 4-nitrophenyl phosphate disodium salt 
hexahydrate (Sigma-Aldrich, Germany) dissolved in 0.1 M AP-buffer (50 mM glycine, 100 mM Tris-Base, 1 mM 
MgCl2 in dH2O) at pH 10.5 for 30 min at 37 °C and absorbance was measured at 405 nm wavelength.
Alkaline phosphatase staining. Cells were fixed with 3.7% v/v formalin for 10 min at room temperature (RT) 
and stained with 0.1% w/v naphtol-AS-MX-phosphate (Sigma-Aldrich, Germany) and 0.6% w/v Echtblausalz 
(Chroma, Germany) in staining buffer (0.5% dimethylformamide, 100 mM Tris-Base, 2 mM MgCl2 in dH2O; pH 
8.5) for 30 min at 37 °C.
Alizarin Red staining and quantification. Cells were fixed with 3.7% v/v formalin for 10 min at RT and incubated 
with 0.5% w/v alizarin red (Sigma-Aldrich, Germany) in dH2O for 10 min at RT. Quantification was done by 
removing staining with 5% w/v SDS in 5 mM HCl and measuring absorbance at 570 nm.
Gene expression. RNA was isolated after 0, 7, 14 and 21 days in culture using the NucleoSpin RNA Kit (Macherey 
Nagel, Germany). The RNA of three wells was pooled resulting in n = 2. RNA (100 ng) was transcribed into com-
plementary DNA (cDNA, qScript cDNA Supermix, Quanta BioSciences, USA) and used 1:20 diluted. RT-PCR 
analysis were run with validated primer sets (for primer sequences see Table 3) and PerfeCTa® SYBR® Green 
SuperMix (Quanta BioSciences, USA). For all primers, amplification efficiencies were analyzed and mean nor-
malized expression (MNE) ratios were calculated using the ΔΔCt method with efficiency correction and normal-
ization to the control (d0 of differentiation) and 18 S ribosomal RNA used as a reference gene.
(3) The effect of AMP2 on cell migration was assessed. Human primary osteoblast-like cells were seeded into 
24-well plates and cultured in cultivation media. After reaching confluence, medium was removed and a cross 
scratch was made using a 10 µl pipette tip using a modified protocol49. Medium plus AMP2 (2–133 µg/l), 0.1% 
FCS (negative control) and 10% FCS (positive control) was added and pictures were taken at time point 0, 24 and 
Figure 9. Two dimensional drawing of the five selected peptides using the PepDraw online software. (A) 
AMP1, (B) AMP2, (C) AMP3, (D) AMP4 and (E) AMP5.
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after 48 hours of cultivation. Using ImageJ software (version 1.4.8.; https://imagej.nih.gov/ij/) the diameter of the 
scratch was measured and the closure over time calculated (n = 3).
Effect against internalized bacteria. Human primary osteoblast-like cells were cultivated in 24-well 
plates with cultivation medium until they reached a minimum confluence of 80%. For the experiment, cells 
were washed and S. aureus (ATCC 29213) in cultivation medium added (~2 × 107 cfu/ml). After an incubation 
of 45 minutes, extracellular bacteria were killed using 200 µg/ml gentamicin dissolved in CM with 10% FCS, 
without P/S. After 1 hour incubation, gentamicin solution was removed, cells washed three times and AMP2 (33 
and 67 µg/ml) in CM with only 1% FCS + no P/S added for 4 and 24 hours. As reference, 7.5 µg/ml rifampicin was 
used. All incubation steps were done in an incubator with 37 °C, 95% humidity and 5% CO2. For determination 
of the internalized bacteria, cells were lysed and the supernatant plated on CA plates. Experiment were done with 
n = 7.
Biofilm. Fluorescence in situ hybridization (FISH) was used to visualize the effect of the AMP2 on a biofilm35. 
S. epidermidis (PIA 8400) biofilm was grown on 5 × 8 mm polyurethane (PU) waver (Epurex Films, Germany) 
in the incubator at 37 °C for 72 hours under aerobic conditions. After biofilm formation, medium was replaced 
by MH++ medium containing different concentrations of the AMP2 (4 or 8 µg/ml) or phosphate buffered saline 
as control. After further 24 hours of incubation on a rotation shaker, waver were removed, fixed and embedded 
in methylmethacrylate (Technovit 8100, Kulzer, Germany) and sectioned as described elsewhere50. To visual-
ize the biofilm, samples were stained with nucleic acid stain DAPI and the Cy3-labeled Staphylococcus-specific 
FISH-probe STAPHY (5′TCCTCCATATCTCTGCGC3′, biomers, Germany) as published51, 52. A nonsense probe 
NON338 labeled in Cy5 was used to exclude unspecific probe binding53. After incubation in a dark, humid cham-
ber for 2 hours at 50 °C, the slides were rinsed with sterile water, dried, and mounted using Vectashield mounting 
medium (Vector Laboratories, Burlingame, CA). Image analysis was done using an epifluorescence microscope 
(Axioplan 2; Carl Zeiss, Jena, Germany) equipped with narrow band filter sets (AHF Analysentechnik, Germany). 
Image acquisition was performed with an AxioCam MRm (Zeiss, Germany) making use of the AxioVision 4.4 
software. Digital image analysis was performed with the daime software54. Per group 10 pictures were randomly 
chosen and analyzed.
Calorimeter. To confirm MIC of the AMP2 by isothermal microcalorimetry32, three different bouillons were 
tested: Mueller-Hinton II bouillon with adjusted cations (MH++; BBL, Germany), Mueller-Hinton bouillon with 
low cations (MH+; with 3–4 mg/l Ca2+ and 5–6 mg/l Mg2+; Oxoid, Germany) and Mueller-Hinton bouillon with-
out cations (MH−; Merck, Germany). AMP2 concentrations of 2–33 µg/ml were tested with the three different 
bouillons and gentamicin concentrations of 0.125–2 µg/ml were analyzed with MH++. Staphylococcus aureus 
(ATCC 29213, 300 µl with 105 cfu/ml) was added to each microcalorimetry glass ampoule (Waters; Germany) 
containing 3.7 ml of AMP or gentamicin solution of (n = 3). The ampoules were hermetically sealed and heat 
flow (W) was measured for 24 hours in the calorimeter TAM III (TA Instruments, USA). For the biofilm assay, 
S. aureus biofilm was grown on glass beads (4 mm diameter, 60 µm pores; ROBU Glasfilter-Geräte, Germany) in 
MH++ bouillon at 37 °C in an aerobe atmosphere for 24 hours. After washing with sodium chloride, beads were 
Gene Name Efficiency
forward (F) 
and reverse (R) 
sequence 3′-5′
18 S 18 S 1.79
F: CGG AAA 
ATA GCC TTT 
GCC ATC
R: AGT TCT 
CCC GCC CTC 
TTG GT
alkaline phosphatase AP 1.81
F: GGA AAT 
CTG TGG GCA 
TTG TG
R: CCC TGA 
TGT TAT GCA 
TGA GC
collagen type I, 
alpha 1 Col1 1.92
F: TGA CCT 
CAA GAT GTG 
CCA CT
R: ACC AGA 
CAT GCC TCT 
TGT CC
runt-related 
transcription factor 2 RUNX2 1.86
F: GCC CCC 
AAA CAG TAT 
CTT GA
R: GCC TGA 
AGT GAG GTT 
TTA GGC
Table 3. All primer pairs were designed with the Primer3web web page and intron spanning. Using the 
OligoAnalyzer 3.1 software all primer pairs were tested for self-dimers, hetero-dimers or hairpin production. 
The amplicon size was chosen between 150–250 base pairs.
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incubated with AMP2 (133, 267, 533 µg/ml) or daptomycin (128 µg/ml) in MH++ bouillon for another 24 hours 
at 37 °C. Beads were washed again and added to the glass ampoule with fresh MH++ bouillon. The total heat (J) 
was measured for 48 hours in the calorimeter. A concentration, which inhibits minimum 90% of biofilm, can be 
defined as the minimal biofilm inhibitory concentration (MICB). All samples were tested with n = 6.
Furthermore, the MBC for biofilms (MBCB) where 99.9% of all bacteria are killed was determined. After 
measurement, bouillon and glass beads were plated on CA plates and incubated for 24 hours at 37 °C in an aerobe 
atmosphere.
AMP coating of implants. Titanium wires (diameter 1 mm, Synthes, USA) were coated with 
Poly(D,L-lactide) (PDLLA, Boehringer Ingelheim, Germany) and incorporated AMP2 at three different concen-
trations: 10% w/w, 20% w/w, or 30% w/w. Gentamicin/PDLLA (10% w/w) or PDLLA coated wires served as con-
trol. Briefly, 100 mg PDLLA was solved in 1.5 ml ethyl acetate and the wires were coated in a dipping procedure. 
Details of the coating were described previously55. Three nails of each group were placed on Mueller-Hinton agar 
plates plated with S. aureus (ATCC 29213) and the zone of inhibition (ZOI) was quantified after 1, 3, 7, and 14 
days using ImageJ software.
Statistical analyses. The data were analyzed with the non-parametric tests Kruskal-Wallis and 
Mann-Whitney (SPSS 22; IBM, USA). The multiple alpha-error was corrected with Bonferroni-Holm post-hoc 
test. Values with p ≤ 0.05 were considered as significant. The effect of FCS concentration on AMP activity was 
analyzed by linear regression.
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